James Culverwell
Chairman

James Culverwell has over 30 years of experience in the pharmaceutical industry in pharmaceutical company analysis, investment banking and healthcare private equity. He established leading global healthcare research franchises at Hoare Govett and Merrill Lynch & Co. In 2004, he set up Sudbrook Associates, a healthcare corporate advisor specialising in fundraising, corporate advice and due diligence in the private healthcare sector. He was a Non-Executive Director (NED) and Chairman of the Audit Committee of Innocoll Holdings quoted on Nasdaq until its sale in 2016 and was a NED of Amryt Pharma, a rare disease company listed on AIM, until its merger with Aegerion in 2019. He is currently NED and Chairman of Audit Committee for NASDAQ-listed companies Quoin Pharmaceuticals and TC Biopharm. He received an MSc from the University of Aberdeen.